Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug;5(4):421-6.
doi: 10.2147/tcrm.s4317. Epub 2009 Jun 22.

Treatment of recurrent epithelial ovarian cancer

Carmela Pisano  1 , Giovanni S Bruni, Gaetano Facchini, Claudia Marchetti, Sandro Pignata
Affiliations

Treatment of recurrent epithelial ovarian cancer

Carmela Pisano et al. Ther Clin Risk Manag. 2009 Aug.

Abstract

Epidemiologic analysis reveals that the mortality rate from ovarian cancer is continuously decreasing due to the improvement of surgery and chemotherapy. However, the prognosis of ovarian cancer patients is still unsatisfactory overall considering that only 30% of patients are alive after five years. In fact, although surgery and first-line systemic chemotherapy induces complete and partial response in up to 80% of patients with about a 25% pathological complete remission rate, recurrences occur in the majority of patients. The role of surgery in recurrent disease has been recently studied and many patients can receive an optimal secondary cytoreduction. Most of the recurrent patients are subject to a number of treatment regimens that, although palliative in nature, are also able to prolong survival. Important results have been obtained in particular in platinum-sensitive recurrent disease where a platinum-based chemotherapy is able to prolong progression-free survival and overall survival. Overall, our armamentarium for the treatment of progressive or recurrent ovarian cancer is significantly richer than in the past, and in many patients it is possible to achieve our goal of controlling the chronic behavior of the disease.

Keywords: chemotherapy; ovarian cancer.

PubMed Disclaimer

References

    1. Bristow RE. Survival effect of maximal cytoreductive surgery for advance ovarian cancer in the platinum era: a metanalysis. J Clin Oncol. 2002;20:1248–1259. - PubMed
    1. du Bois A, Quinn M, Thigpen T, et al. for the Gynecologic Cancer Intergroup. AGO-OVAR. ANZGOG. EORTC. GEICO. GINECO. GOG. JGOG. MRC/NCRI. NCIC-CTG. NCI-US. NSGO. RTOG. SGCTG. IGCS. Organizational team of the two prior International OCCC consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol. 2004;2005;16(Suppl 8):viii7–viii12. - PubMed
    1. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 1999;93:21–24. - PubMed
    1. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9:1801–1805. - PubMed
    1. Parmar MK, Ledermann JA, Colombo N, et al. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: the ICON4/AGOOVAR- 2.2 trial. Lancet. 2003;361:2099–2106. - PubMed